News

ATCC Announces Award from NIAID to Consolidate its BEI Resources and NIH HIV Reagent Programs

ATCC, the world’s premier biological materials management and standards organization, today announced a seven-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to continue the management of the BEI Resources Program. NIAID has made an initial award of over $21.5 million, with further funding expected if all project milestones are met. This contract will merge the NIH HIV Reagent Program with the BEI Resources Program under the Biological and Emerging Infections Research Resources Program (BEI-RRP) umbrella. ATCC has managed the BEI Resources Program since 2003 and the NIH HIV Reagent Program since 2020. This important merger will allow researchers to have streamlined access to all priority pathogens for human health under one program.

“Through our successful collaboration with NIAID, we have helped consolidate ten other repositories that provide critical materials to the infectious disease research community,” said ATCC chairman and CEO Raymond H. Cypess, DVM, Ph.D. “At ATCC, we understand why curated, high-quality biomaterials, reagents, and products are critical to achieving credible research results. We also recognize why streamlining access to these items is essential so researchers can develop the diagnostic tests, vaccines, and therapies needed to improve human health.”

The BEI-RRP will continue to serve as a vital centralized repository of quality-assured organisms, reagents, tools, services, and information related to the NIAID research portfolio. Priority infectious diseases supported by BEI-RRP include Category A, B, and C priority pathogens, emerging infectious diseases, HIV/AIDS, and non-pathogenic microbes. These priorities may change as scientific research and public health needs shift. At the discretion of NIAID, it will also be a resource for materials produced by other government-supported research projects and service programs.

Under the management of ATCC, the BEI-RRP will receive, acquire, authenticate, produce, preserve, store, deaccession, dispose, and distribute most organisms and reagents. The program is expected to serve approximately 15,000 registered researchers from the US and other countries and will include approximately 17,000 unique items in its online catalog.

“Over the past 20 years, we have built a solid rapport with NIAID based on our expertise in biological resource development and management,” said Rebecca Bradford, MBA, MS, Vice President of Government Programs within ATCC Federal Solutions. “In doing so, BEI Resources has become instrumental to public health by providing the roadmap and capability to supply critical reagents in response to infectious disease events, resulting in accelerated medical countermeasures. We look forward to continuing to support NIAID’s global health efforts.”

This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health, and Human Services under Contract No. 75N93024C00001.

 

Learn more here.

Recent News

05/08/2026

RIVANNA Receives FDA 510(k) Clearance for Accuro XV Musculoskeletal Ultrasound Imaging System

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Accuro® XV Diagnostic Ultrasound System. The clearance marks a pivotal regulatory milestone for RIVANNA, authorizing commercial use of the Accuro XV for musculoskeletal imaging by qualified and trained healthcare professionals in hospital

05/06/2026

RoVa Labs Opens as Transformational Investment in Roanoke Region’s Innovation Economy

Leaders from Carilion Clinic, the City of Roanoke, Roanoke Blacksburg Innovation Alliance (RBIA), and Virginia Western Community College cut the ribbon on years of hard work with the opening of RoVa Labs, a 40,000-square-foot biotech incubator designed to accelerate commercialization, strengthen the Roanoke Innovation Corridor, and position the region as an emerging destination for life

05/04/2026

ISOThrive Reports Highly Statistically Significant Phase 2 Data for MHS-1031 in NERD PPI-Partial Responder Patients at DDW 2026

ISOThrive Inc. announced positive Phase 2 results for MHS-1031 treating NERD patients with incomplete response to proton pump inhibitors (PPIs), demonstrating statistically significant and clinically meaningful reductions in heartburn incidence, severity, and regurgitation. The company’s Chief Medical Officer is presenting these results at Digestive Disease Week (DDW) 2026 this week. NERD represents approximately 70% of